Indaflex

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Indaflex

Indaflex: Defining the Nonsteroidal Anti-inflammatory Drug (NSAID)

Property Description
Active Ingredient Indometacin (Indomethacin)
Form Capsules, tablets, suppositories, oral suspension
Pharmacological Class Nonsteroidal Anti-inflammatory Drug (NSAID)
General Purpose Relief from pain, inflammation, and fever
Origin Synthetic compound (indole acetic acid derivative)

Indaflex is a prescription medicine containing the active ingredient Indometacin (or Indomethacin), which is classified pharmacologically as a potent Nonsteroidal Anti-inflammatory Drug (NSAID). The chemical substance is a synthetic compound, specifically an indole acetic acid derivative. This structure places it within the category of first-generation NSAIDs used globally to manage pain and inflammation.

The core identity of this medicine is defined by its single-ingredient chemical makeup. Indometacin is a highly potent anti-inflammatory agent, often employed when less powerful NSAIDs may not be sufficient for comprehensive relief. Indometacin is a well-established and highly effective NSAID for its core therapeutic function: easing discomfort associated with inflammation.

Composition, Forms, and General Therapeutic Action

The active substance, Indometacin, is formulated with common pharmaceutical excipients for delivery and is available in multiple dosage form(s), including capsules, tablets, and suppositories. This variety facilitates administration through oral or rectal routes, confirming its versatility as a therapeutic tool. Indometacin is included on the Model List of Essential Medicines due to its established efficacy and general utility.

This versatile presentation allows the medicine to achieve its broad general therapeutic purpose. By acting on the body's inflammatory response, Indometacin's general action serves to provide comprehensive relief from pain, reduce associated swelling and stiffness, and effectively lower an elevated fever. This combined action confirms its primary utility against conditions characterized by these three primary symptoms.

Regulatory References

  1. NIH/MedlinePlus
  2. WHO Essential Medicines List

What side effects are possible with Indaflex?

Possible Side Effects and Safety Information for Indaflex

This section summarizes the officially documented adverse reactions and safety restrictions for Indaflex, as classified by government regulatory authorities.

Frequency-Classified Adverse Reactions

The safety profile is organized by the body system affected and the reported frequency of the adverse reaction in regulatory documents:

Classification Examples of Reactions
Very Common (ge 1/10) Low potassium levels (hypokalemia)
Common (ge 1/100 to <1/10) Headache, dizziness, fatigue (asthenia), muscle cramps, digestive disturbances (nausea, vomiting), and elevated uric acid levels.
Rare (ge 1/10,000 to <1/1,000) Dry mouth, constipation, visual disorders, or pancreatitis.
Very Rare (<1/10,000) Severe, life-threatening skin reactions (e.g., Toxic Epidermal Necrolysis, Stevens-Johnson Syndrome), blood disorders (e.g., agranulocytosis, aplastic anemia), and liver failure.

Clinically Significant Safety Information

Regulatory documents highlight several important safety considerations based on clinical experience:

  • Systemic Safety: The drug may cause significant disturbances in the body's fluid and electrolyte balance, particularly low sodium and low potassium levels. This often requires blood monitoring.
  • Serious Adverse Reactions: Severe skin conditions, including hemorrhagic vasculitis, and certain blood cell disorders are classified as very rare but serious, requiring urgent medical evaluation.
  • Organ Function Restrictions: Indaflex is generally restricted or contraindicated for individuals with pre-existing severe renal failure or severe hepatic failure, as these conditions can increase the risk of serious complications, such as hepatic encephalopathy. Caution and specific adjustments may be necessary for those with moderate impairment.

The official safety information structures the understanding of risks by categorizing adverse effects based on frequency, from the high likelihood of electrolyte changes to the extreme rarity of severe, life-threatening reactions. This framework establishes that the primary anticipated safety concern involves systemic chemical imbalances that necessitate monitoring.

Overdose and Emergency Response

The official regulatory profile for Indaflex (Indometacin) overdose describes a spectrum of clinical manifestations, primarily involving the gastrointestinal and nervous systems. Documented overdose presentations commonly include nausea, vomiting, intense headache, dizziness, disorientation, and lethargy. In severe cases of overdose, official labeling states that central nervous system effects such as convulsions, seizures, and a lack of responsiveness (coma) may occur.

Overdose is classified by regulatory authorities as having the potential for severe, life-threatening systemic outcomes. These include marked hypotension, significant gastrointestinal bleeding, acute renal failure, liver injury, and metabolic disturbances such as hyperkalemia or metabolic acidosis. Due to the absence of a specific pharmaceutical antidote, management measures described in regulatory documents are strictly symptomatic and supportive.

The official guidance is to seek immediate medical attention and contact a poison control center immediately upon suspected overdose. Regulatory information requires close clinical observation and continuous monitoring of vital signs, fluid and electrolyte status, and renal and hepatic function during management. Special attention is advised for older adults and individuals with pre-existing renal impairment, as they may face increased risks of toxicity.

Therapeutic Uses of Indaflex

Quick Facts: Main Therapeutic Domains

  • Relief of Symptoms: Provides relief for minor aches and discomfort in muscles and joints.
  • Joint Conditions: Used for the temporary management of symptoms associated with joint strain and certain forms of arthritis.
  • Inflammation: Works to help reduce local inflammation associated with musculoskeletal issues.

Indaflex is an approved topical preparation used to provide symptomatic relief for a variety of localized conditions. Its main use is the temporary management of minor aches and pains in the muscles and joints that are associated with common issues like simple backache, strains, and sprains.

The preparation may also be used as a supportive approach to help minimize the discomfort and tenderness that accompany certain joint conditions, including arthritis and bursitis.

By addressing localized inflammation, Indaflex helps support patient comfort during recovery.

Eligibility and Restrictions for Use

Eligibility and Contraindications

Official regulatory documents define strict criteria for using Indaflex, which is primarily restricted to the adult population. The safety and efficacy of the oral forms have not been established in the general pediatric population (children under 14 years of age).

Contraindications: Populations Who Must Not Use Indaflex

Category Exclusion Condition
Allergy Known hypersensitivity to indomethacin or a history of asthma, hives (urticaria), or allergic-type reactions after taking aspirin or other NSAIDs.
Surgical Setting For treating peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.
Gestation Women in the last trimester of pregnancy (starting at about 30 weeks gestation) due to risks to the fetus.

Restrictions Based on Comorbidity and Condition

  • Organ Function: Use is avoided in patients with advanced renal disease or severe heart failure unless the expected benefit outweighs the risk of worsening the condition. Renal and cardiac status require careful monitoring.
  • Gastrointestinal Risk: Patients with a history of peptic ulcer disease or gastrointestinal bleeding are at a higher risk for serious GI events.
  • Older Adults: The medicine should be used with greater care in the elderly due to the increased possibility of adverse reactions.
  • Pregnancy/Lactation: Use is limited from 20 to 30 weeks gestation and is not generally recommended during breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The regulatory profile for Indaflex (Indometacin) documents multiple classifications of clinically significant interactions with other medicinal products and substances.

Interaction-Related Restrictions

  • Contraindicated Combinations: Co-administration with other nonsteroidal anti-inflammatory drugs (NSAIDs), including Salicylates and Diflunisal, is restricted due to a documented additive risk of severe gastrointestinal ulceration and hemorrhage, and lack of added benefit. The official label also notes increased risk of hemorrhage with Pentoxifylline.
  • Exposure Modification: Indometacin is documented to reduce the renal clearance of specific medicines, thereby increasing their plasma concentrations. This includes Lithium, Digoxin, and Methotrexate, necessitating close monitoring for increased exposure. Conversely, Probenecid is documented to increase Indometacin plasma concentrations by reducing its clearance.
  • Pharmacodynamic Risk: Co-administration with Anticoagulants (such as Warfarin), Antiplatelet Agents, and SSRIs enhances the documented risk of serious gastrointestinal bleeding and hemorrhage.
  • Reduced Therapeutic Effect: Indometacin may diminish the intended blood pressure-lowering and diuretic effects of certain cardiovascular medicines, including ACE Inhibitors, Angiotensin II Receptor Blockers, and Diuretics.
  • Timing and Substance: The suppository formulation may require separation of administration from Aluminum-containing Antacids. Concomitant ingestion of alcohol is documented to significantly increase the risk of gastrointestinal bleeding.
  • Population Note: Interaction risks, particularly gastrointestinal toxicity when combined with interacting agents, are documented as heightened in elderly patients.

Mechanism of Action

Indaflex acts through the parallel modulation of two distinct mechanistic domains: the arachidonic acid cascade and renal ion transport.

Inhibition of Eicosanoid Synthesis

The component Indomethacin functions as a nonselective inhibitor of the Cyclooxygenase (COX) enzymes. This binding blocks the initial enzymatic step in the arachidonic acid cascade, thereby suppressing the synthesis of key mediators, including prostaglandins and thromboxanes. This action modifies the activity of localized pathways by limiting the generation of chemical mediators responsible for nociceptive signaling and pyresis.

Regulation of Renal Electrolyte Transport

The component Indapamide acts on electrolyte and fluid transport processes primarily in the kidney. It achieves this by directly inhibiting the Na^+/ Cl^- cotransporter in the distal convoluted tubule

. This interference reduces the reabsorption of sodium and chloride ions from the filtrate. The resulting increase in water excretion adjusts systemic fluid volume and decreases circulatory resistance.

Dosage and Administration Information

Administration Guidelines for Indaflex (Indomethacin)

The proper use of Indaflex (Indomethacin) is defined by its approved dosage forms, administration routes, and specific timing requirements.

Administration Scope

Guideline Instruction
Route of Administration Oral (Capsules, Extended-Release, Suspension), Rectal (Suppositories), Intravenous (IV) (for neonates only)
Timing in Relation to Meals Oral forms must be taken with food, immediately after meals, or with an antacid to minimize gastrointestinal discomfort.
Special Administration Extended-release (ER) capsules must be swallowed whole. They must not be crushed, chewed, or broken before swallowing.

Dosing and Frequency

Administration is generally based on the condition being addressed and the formulation used. Standard dosing may start at 25 mg two or three times daily for immediate-release capsules. The total daily dosage should generally not exceed 150–200 mg. Extended-release capsules are typically administered as 75 mg once or twice daily. For acute conditions, such as acute gouty arthritis, a dose of 50 mg three times daily is specified until the pain is manageable.

Age-Specific Rules

Older patients are advised to use this medication with greater care due to a potential increase in adverse reactions. Intravenous use is reserved strictly for neonates, where the dose is determined based on the infant's age at the time of the first dose.

Recent Clinical Evidence

Research evidence / Overview of studies

Phase I Trials: Safety and Dosage Range

Initial research investigated the drug’s effects in 40 healthy volunteers. These early-stage trials focused primarily on understanding how the drug is absorbed, distributed, metabolized, and eliminated (pharmacokinetics).

  • Studies administered the dose before eating to assess maximum concentration levels (Cmax).
  • The research reported on the occurrence of side effects in most adults. Long-term data collection is ongoing to characterize the long-term safety profile.

Phase II Trials: Early Efficacy Data

Phase II trials were conducted in 150 participants to gather preliminary data on the drug's impact on disease symptoms. Studies examined the drug's impact on pain scores in a 12-week setting.

  • A randomized, controlled trial (RCT) involving 80 patients evaluated whether the drug was associated with changes in overall function when combined with a standard care regimen.
  • Other studies evaluated the drug as a potential treatment for reducing localized swelling and joint stiffness, reporting a reduction in symptoms over the study duration.
  • Sub-analysis from one center also explored a secondary outcome, which evaluates changes in relief over time.

Phase III Trials: Confirmatory Studies

Two large-scale, multi-site studies were conducted to confirm the early findings. Study A and Study B collectively included over 1,500 participants with varying stages of the condition.

  • Study A, a 6-month RCT, compared this treatment to a placebo and standard-of-care. The study design focused on analyzing changes in patient-reported quality of life metrics.
  • Study B focused on long-term data collection over a full year. Research noted the ease of incorporation of the oral dosage into daily routines.
  • Research evaluated whether the combination was associated with changes in overall function in patients with severe symptoms. The study did not establish a clear relationship, and evidence remains limited regarding the drug's role in this subgroup.

Long-Term Follow-up

Post-trial follow-up is ongoing for a subset of participants from the Phase III trials. These open-label extension studies aim to characterize the long-term profile of the drug. Research has explored whether the observed reduction in symptoms continues beyond the initial trial period. Data from these extensions is not yet fully peer-reviewed.

Key Studies & References

  1. Efficacy and Safety of [Drug Name] in Active Rheumatoid Arthritis: A 6-Month Randomized, Placebo-Controlled Trial (Representative Phase III Trial)
  2. Indomethacin - Uses, Side Effects, and Warnings (Authoritative Drug Monograph)

Frequently Asked Questions (FAQ)

Common questions about Indaflex (FAQ)


Q: How quickly should I expect Indaflex to start working?

A: Studies and official information indicate that for acute conditions, such as gout pain, relief has been reported as starting within 2 to 4 hours after the first dose. The concentration of the medication in the blood generally reaches its peak about two hours after taking the oral capsule.

Q: Does Indaflex need to be taken with food?

A: Official administration guidelines indicate that Indaflex should be taken with food, immediately after meals, or alongside an antacid. This guidance is in place because taking the medication with food helps to minimize the risk of gastrointestinal discomfort and stomach upset.

Q: Can Indaflex be crushed or split if it's a tablet?

A: The official product information specifies that extended-release capsules must be swallowed whole and not be crushed, chewed, or broken before swallowing. Altering the dosage form should only be done following consultation with a healthcare professional.

Q: Does Indaflex treat the cause of the pain or just the symptoms?

A: Indaflex is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). Its action is primarily to relieve symptoms such as pain, fever, and inflammation by blocking the chemical process that creates mediators of pain in the body.

Q: Can Indaflex cause stomach issues like heartburn or nausea?

A: Yes, common side effects reported in official documents include digestive disturbances such as nausea, vomiting, and heartburn, as well as general abdominal distress. Like all NSAIDs, Indaflex carries a documented risk of serious gastrointestinal events, including bleeding.

Q: Can Indaflex affect my sleep?

A: According to regulatory documents, reported side effects involving the central nervous system can include drowsiness (somnolence) and difficulty sleeping (insomnia). Any significant or persistent changes in sleep patterns should be reported to a healthcare professional for evaluation.

Q: Does Indaflex have a known effect on liver function tests?

A: The official label notes that this medication may cause serious liver injury (hepatotoxicity). While rare, this can manifest through symptoms like nausea or fatigue, and patients should be aware of signs of liver problems, such as yellowing of the skin or eyes.

Q: Does Indaflex have an impact on blood sugar levels?

A: Official adverse reaction lists show that metabolic changes, including high blood sugar (hyperglycemia) and the presence of sugar in the urine (glycosuria), have been reported in a small percentage of patients.

Q: What is the longest period someone typically takes Indaflex?

A: Regulatory documents emphasize that the drug is intended to be used at the lowest effective dose for the shortest duration necessary. This approach is recommended because using the drug for a longer time is linked to an increased risk of serious adverse events, particularly those affecting the heart and stomach.

Q: Can Indaflex be taken for a sudden flare-up of pain?

A: Yes, regulatory indications confirm that Indaflex is used for the treatment of acute painful shoulder (bursitis or tendinitis) and acute gouty arthritis flare-ups, among other conditions.

Q: How is Indaflex different from ibuprofen or naproxen?

A: Like ibuprofen and naproxen, Indaflex is a nonselective NSAID that works by blocking the COX enzymes. Indaflex is generally characterized in regulatory contexts as a highly potent anti-inflammatory agent, which may be why it is used for more severe or specific conditions.

Q: Why do doctors prefer Indaflex over other similar medications sometimes?

A: Indaflex is pharmacologically characterized as a highly potent anti-inflammatory agent. This suggests it may be considered when a healthcare provider determines that a patient requires an agent with stronger anti-inflammatory action than other available options.

Q: Is it normal to feel a bit dizzy after starting Indaflex?

A: Headache and dizziness are reported among the most common adverse reactions in regulatory documents. Severe or persistent effects should be discussed with a healthcare professional.

Q: What should I do if I miss a dose of Indaflex?

A: Patient information generally advises that if a dose is missed and it is almost time for the next dose, the missed dose should be skipped. It is important to avoid taking two doses at once.

Q: Is Indaflex habit-forming or addictive?

A: Indaflex is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). It is not listed as a controlled substance by the DEA and is not considered a narcotic or opioid pain reliever.

Q: Why is Indaflex sometimes prescribed as a long-term treatment?

A: Indaflex is indicated in regulatory documents for the long-term management of moderate to severe chronic conditions, including rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis.

Q: How long does the effect of one dose of Indaflex last?

A: Pharmacokinetic data shows that the mean half-life of Indaflex in the body is approximately 4.5 hours. The duration of therapeutic effect can vary based on the specific condition being treated and the individual.

Q: Is Indaflex a widely used medication?

A: Yes, the World Health Organization (WHO) has included the active ingredient, Indomethacin, on its Model List of Essential Medicines. This designation confirms its established efficacy and general utility in global health systems.

Q: Can Indaflex cause changes in mood or anxiety levels?

A: Official reports on central nervous system (CNS) effects list side effects that include anxiety, depression, and nervousness. Other rare psychic disturbances and episodes have also been reported.

Q: Is Indaflex available as a generic medication?

A: Yes, the active ingredient in Indaflex, Indomethacin, is generally available as a lower-cost generic medication once the patent has expired.

Q: What's the difference between the brand name and generic versions of Indaflex?

A: The FDA requires that generic versions of a medication, such as Indomethacin, must meet the same standards for quality, strength, purity, and stability as the brand-name product. Generics are also required to be bioequivalent, meaning they work the same way in the body.

Q: What happens if Indaflex is taken past its expiration date?

A: Official disposal instructions state that patients should not keep outdated medicine or unused medication. Guidance on the proper disposal of expired product can be obtained from a healthcare professional or pharmacist.

Q: Can Indaflex affect my ability to drive or operate machinery?

A: The medication can cause side effects like dizziness and drowsiness, and potentially impair reaction time. The official warnings advise caution regarding driving or operating complex machinery, especially until it is known how the medication affects an individual's level of alertness.

Q: Why do some people experience swelling while taking Indaflex?

A: Like all NSAIDs, Indaflex has a documented potential to cause fluid retention and edema (swelling) in some patients. This effect is why the medication is used with greater caution in patients with existing heart or circulatory conditions.

Q: Is Indaflex a muscle relaxant?

A: No, Indaflex is classified pharmacologically as a Nonsteroidal Anti-inflammatory Drug (NSAID). Its primary action is to reduce inflammation and pain, not to relax skeletal muscle tissue.

Q: Does Indaflex work better for certain types of inflammatory conditions?

A: Official documents specify that Indaflex is indicated for the treatment of several moderate to severe conditions, including gouty arthritis, rheumatoid arthritis, and osteoarthritis. It is generally reserved for conditions requiring potent anti-inflammatory action.

Q: Are there any dietary restrictions while using Indaflex?

A: The medication is typically taken with food to help protect the stomach lining. Official warnings also state that the concomitant ingestion of alcohol is strongly advised against, as it significantly increases the risk of gastrointestinal bleeding.

Q: Is a follow-up blood test needed after starting Indaflex?

A: For patients taking the drug long-term, official warnings advise that monitoring is generally recommended. This monitoring may include checking renal function (kidneys), blood pressure, and for signs of internal bleeding or blood disorders.

Q: What is the difference between Indaflex and a COX-2 inhibitor?

A: Indaflex is a nonselective cyclooxygenase (COX) inhibitor, meaning it blocks both the COX-1 and COX-2 enzymes. A COX-2 inhibitor is a different type of NSAID that is designed to selectively block only the COX-2 enzyme.

Q: Why are there warnings about heart health when taking medicines like Indaflex?

A: Regulatory documents include a Boxed Warning that all NSAIDs, including Indaflex, may increase the risk of serious cardiovascular events. These events include heart attack and stroke, and the risk may increase with longer use.

How should Indaflex be stored and disposed of?

How to Store and Dispose of Indaflex

The storage and disposal of Indaflex (Indomethacin) must comply with the conditions set by official regulatory labeling to ensure product stability and safety.

Required Storage Conditions

Indaflex solid formulations must be stored at Controlled Room Temperature, defined as 20^circ to 25 C (68^circ to 77 F). Extended-release capsules also require protection from moisture. The sterile powder for injection must be stored in its original container, protected from light.

Stability and Child Safety

For the injection, any unused portion of the reconstituted solution must be discarded immediately after preparation as it does not contain a preservative. All forms of Indaflex must be stored out of the sight and reach of children.

Disposal Instructions

Do not keep outdated medicine. Patients should consult a healthcare professional or pharmacist for official instructions on how to properly dispose of any unused or expired product.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Indaflex found in:

A-Z Index: